Vitiligo - Pipeline Review, Q2 2011
Global Markets Direct’s, 'Vitiligo - Pipeline Review, Q2 2011', provides an overview of the Vitiligo therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. 'Vitiligo - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Vitiligo.
- A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vitiligo pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Vitiligo.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers an
Vitiligo – Pipeline Review, Q2 2011 Vitiligo - Pipeline Review, Q2 2011 Reference Code: GMDHC1084IDB Publication Date: April 2011 Vitiligo – Pipeline Review, Q2 2011 GMDHC1084IDB / Pub April 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Vitiligo – Pipeline Review, Q2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Vitiligo Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Vitiligo 8 Vitiligo Therapeutics under Development by Companies 10 Vitiligo Therapeutics under Investigation by Universities/Institutes 11 Late Stage Products 12 Comparative Analysis 12 Mid Clinical Stage Products 13 Comparative Analysis 13 Pre-Clinical Stage Products 14 Comparative Analysis 14 Vitiligo Therapeutics - Products under Development by Companies 15 Vitiligo Therapeutics - Products under Investigation by Universities/Institutes 16 Companies Involved in Vitiligo Therapeutics Development 17 Clinuvel Pharmaceuticals Limited 17 SWITCH Biotech LLC 17 Vitiligo - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 Scenesse - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 SWT05104 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SWT05105 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 VAL-003 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Autologous Transplantation of Melanocytes - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Vitiligo – Pipeline Review, Q2 2011 GMDHC1084IDB / Pub April 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Vitiligo – Pipeline Review, Q2 2011 Etanercept - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Tacrolimus Ointment + TL01 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Autologus Melanocytes + PUVA Therapy - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Melanocyte-Keratinocyte Transplantation - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Vitiligo Therapeutics – Drug Profile Updates 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 36 Contact Us 36 Disclaimer 36 Vitiligo – Pipeline Review, Q2 2011 GMDHC1084IDB / Pub April 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Vitiligo – Pipeline Review, Q2 2011 Lis t o f Ta b le s Number of Products Under Development for Vitiligo, Q2 2011 8 Products under Development for Vitiligo – Comparative Analysis, Q2 2011 9 Number of Products under Development by Companies, Q2 2011 10 Number of Products under Investigation by Universities/Institutes, Q2 2011 11 Comparative Analysis by Late Stage Development, Q2 2011 12 Comparative Analysis by Mid Clinical Stage Development, Q2 2011 13 Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 14 Products under
Pages to are hidden for
"Vitiligo - Pipeline Review, Q2 2011"Please download to view full document